{
    "clinical_study": {
        "@rank": "95579", 
        "arm_group": {
            "arm_group_label": "IPI-145/Placebo", 
            "arm_group_type": "Experimental", 
            "description": "Capsules"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the effects of multi-dose regimens of IPI-145 on\n      lung function in mild asthmatic subjects following allergen challenge."
        }, 
        "brief_title": "A Phase 2a, Efficacy and Safety Study of IPI-145 in Mild Asthmatic Subjects", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "This is a phase 2a, randomized, double-blind, placebo-controlled, multi-dose, 2-way\n      cross-over study designed to examine the effect of IPI-145 on lung function and inflammatory\n      indices in mild, allergen-reactive asthmatic subjects undergoing allergen challenge."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adults between 18 and 60 years of age\n\n          -  Diagnosis of asthma (mild) for at least 6 months prior to Screening\n\n          -  Forced expiratory volume in one second (FEV1) \u226570% of predicted value at Screening\n\n          -  A positive skin prick test to test allergen\n\n        Exclusion Criteria:\n\n          -  Any prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor other than\n             IPI-145 in a previous clinical study\n\n          -  Acute asthma exacerbations within 6 weeks prior to Screening\n\n          -  Use of any medication for the treatment of asthma other than a short-acting \u03b22\n             agonist (as needed) within the 4 weeks prior to Screening\n\n          -  Participation in another clinical study within minimum of 30 days prior to study\n             Screening\n\n          -  A positive screen result for active or latent tuberculosis\n\n          -  A history of cardiovascular disease\n\n          -  The concomitant use of acid-reducing agents and cholinesterase inhibiting medication\n\n          -  Inadequate hepatic function defined by Aspartate Aminotransferase (AST) and/or\n             Alanine Aminotransferase (ALT) greater than 1.5 times greater limit of normal (ULN)\n\n          -  Inadequate renal function defined by serum creatinine greater than 2.0 milligrams/dL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653756", 
            "org_study_id": "IPI-145-03", 
            "secondary_id": "2012-001729-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "IPI-145/Placebo", 
                "description": "Active drug", 
                "intervention_name": "IPI-145, a PI3K Inhibitor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IPI-145/Placebo", 
                "intervention_name": "Placebo to match IPI-145", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Asthma", 
            "Allergen Challenge"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grosshansdorf", 
                        "country": "Germany"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of IPI-145 in Mild Asthmatic Subjects Undergoing Allergen Challenge", 
        "overall_contact": {
            "email": "Laura.Alexander@infi.com", 
            "last_name": "Laura Alexander, Msc.", 
            "phone": "(617) 453-1426"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Forced Expiratory Volume in one second (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum concentration (Cmax), Area Under the Curve, and terminal elimination half-life (T1/2) pre-dose and up to 12 hours post dose", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of informed consent through 21 days following study drug administration"
            }, 
            {
                "measure": "Change in C-reactive Protein (CRP) levels", 
                "safety_issue": "No", 
                "time_frame": "Screening and/or Day 1 of each treatment period"
            }
        ], 
        "source": "Infinity Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Infinity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}